Join

Compare · MGTX vs RVMD

MGTX vs RVMD

Side-by-side comparison of MeiraGTx Holdings plc (MGTX) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MGTX and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • RVMD is the larger of the two at $31.57B, about 37.5x MGTX ($841.8M).
  • Over the past year, MGTX is up 43.5% and RVMD is up 265.7% - RVMD leads by 222.2 points.
  • RVMD has been more active in the news (5 items in the past 4 weeks vs 3 for MGTX).
  • RVMD has more recent analyst coverage (25 ratings vs 3 for MGTX).
PerformanceMGTX+43.52%RVMD+265.68%
2025-06-09+0.00%2026-06-08
MetricMGTXRVMD
Company
MeiraGTx Holdings plc
Revolution Medicines Inc.
Price
$9.09+0.94%
$148.49-0.48%
Market cap
$841.8M
$31.57B
1M return
-6.24%
+4.07%
1Y return
+43.52%
+265.68%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2018
2020
News (4w)
3
5
Recent ratings
3
25
MGTX

MeiraGTx Holdings plc

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.

RVMD

Revolution Medicines Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.

Latest MGTX

Latest RVMD